NEW YORK, July 14, 2026, 11:10 EDT
- NextCure shares jumped 176.6% to $6.03 by 10:55 a.m. EDT after touching $11.10, with volume exceeding 81 million shares.
- Existing NextCure shareholders are expected to own 1.21% of the combined company, down from 1.89% before a net-cash adjustment.
- At least $251 million, or 78%, of the announced $320 million financing consists of convertible notes and interest being exchanged for shares rather than fresh cash.
NextCure, Inc. NASDAQ:NXTC shares nearly tripled on Tuesday after the cancer-drug developer agreed to merge with privately held Avere Therapeutics and pair the transaction with a $320 million financing. Yet current holders are expected to own just 1.21% of the combined company, making the rally a wager on a possible cash distribution, a contingent-value right and a higher public valuation for Avere—not merely the financing headline.
At 10:55 a.m. EDT, NextCure was up 176.6% at $6.03 after opening at $9.22 and reaching an intraday high of $11.10. Volume had risen to 81.4 million shares, about 20 times the 4.07 million basic shares outstanding at June 30, though the same shares can change hands repeatedly. The turnover points to event-driven trading, not a settled valuation.
Of the $320 million private placement, $251 million of convertible notes plus accrued interest will convert into equity at closing. At least 78% of the package is therefore a debt rollover, leaving no more than $69 million as new cash subscriptions before the additional interest is counted. The headline number overstates fresh cash.
The merger agreement sets Avere’s pre-financing equity value at $250 million and adds the actual financing proceeds to its transaction value. NextCure starts with an $11 million valuation, but that figure is reduced when its final net cash falls below the deal target; the expected ownership split drops from 1.89% before this adjustment to 1.21%. Assuming the full $320 million financing closes, the disclosed split implies roughly $7 million of merger value for NextCure, or about $1.72 for each June 30 basic share, before any dividend or contingent payment. The adjustment matters more than the headline.
| Deal and market measure | Value | Investor reading |
|---|---|---|
| Announced private placement | $320 million | Includes converted notes |
| Convertible notes, plus interest | At least $251 million | At least 78% of the package |
| Maximum non-note component | No more than $69 million | Actual fresh cash may be lower |
| Avere value before financing | $250 million | Starting value in the exchange formula |
| NextCure ownership | 1.89% before adjustment; 1.21% expected | Final split depends on net cash |
| Implied NextCure merger allocation | About $7.0 million, or $1.72 per basic share | Assumes the full financing closes |
| NXTC basic equity value at $6.03 | About $24.5 million | Roughly $17.6 million above the implied allocation |
The market-value comparison is directional because Tuesday’s figure uses basic shares, while the merger exchange calculation is made on a fully diluted basis. Even so, the gap is material. At $6.03, investors were assigning about $17.6 million beyond the inferred merger allocation to some mix of a permitted pre-closing dividend, future CVR proceeds, speculative trading and the prospect that Avere commands a richer valuation after listing. The stock is trading on a package, not a single asset.
NextCure held $29.7 million in cash, cash equivalents and marketable securities at March 31, but the agreement permits a dividend only to the extent final net cash exceeds the deal target after liabilities and transaction costs. The company also expects about $1.9 million of restructuring charges as it cuts a substantial majority of its workforce, has stopped new U.S. enrollment in the SIM0505 study and has opted out of further LNCB74 cost-sharing. Those moves conserve cash but narrow the legacy pipeline.
The contingent-value right, or CVR, would give holders 90% of net proceeds from licensing, selling or otherwise monetizing NextCure’s legacy assets for two years after closing. The SEC filing says there is no assurance that the CVR will produce a payment, and the right will not be transferable. The legacy option is real, but it is not cash.
Avere’s lead drug, AVR-001, is an oral blocker of the IL-23 receptor with a reported half-life of about 100 hours, designed for once-weekly dosing in plaque psoriasis. A global Phase 2b trial is planned for early 2027, with results expected in the first half of 2028; Chief Executive Andrew Cheng said the financing provides a “clear line of sight to potentially value-generating clinical data.” Convenience is the pitch; proof is later. NextCure, Inc.
That proof will arrive against an established benchmark. Johnson & Johnson NYSE:JNJ and Protagonist Therapeutics NASDAQ:PTGX secured U.S. approval in March for ICOTYDE, a once-daily oral IL-23 receptor antagonist, based on four Phase 3 studies involving about 2,500 patients. Avere’s efficacy case so far rests on a cross-trial comparison—separate studies rather than a head-to-head test—after four weeks of Phase 1b dosing. The clinical bar is already commercial.
| Product measure | AVR-001 | ICOTYDE |
|---|---|---|
| Developer | Avere Therapeutics | Johnson & Johnson and Protagonist |
| Current status | Phase 1b | FDA approved March 18, 2026 |
| Intended dosing | Once weekly | Once daily |
| Evidence cited | Four-week Phase 1b cross-trial comparison | Four Phase 3 studies; about 2,500 patients |
| Next major milestone | Global Phase 2b start in early 2027; results in first half of 2028 | U.S. commercial benchmark already established |
But the merger still requires shareholder approvals, an effective registration statement, Nasdaq clearance and at least $150 million of financing proceeds, including the converted notes. Final ownership can move with NextCure’s net cash, AVR-001 could disappoint in later-stage trials, and the CVR may pay nothing. Avere also faces an approved rival well before its planned 2028 readout. The market wants proof.
The companies expect to close the transaction in the third quarter, rename the combined business Avere Therapeutics and trade under the planned Nasdaq symbol AVRX. For NextCure investors, the next hard numbers are the final net-cash calculation, any dividend declaration and the detailed CVR terms—not the $320 million headline alone. NextCure Chief Executive Michael Richman called the deal a “compelling opportunity for NextCure’s stockholders,” but Tuesday’s price already pays for several outcomes. Timing matters here. NextCure, Inc.
